Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAN-COMBO pragmatic trial of mCombriax in older adults
2026-526720-49-00Phase 4Authorised
- Sponsor
- Gentofte Hospital, Moderna Inc.
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of mCOMBRIAX, JN.1-adapted COVID-19 vaccine and Efluelda in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Gentofte Hospital, Moderna Inc. Primary endpoints: Medically attended influenza and/or COVID-19 and Influenza and/or COVID-19 hospitalization. Planned start Sep 2026; status: authorised.
02
Drugs
mCOMBRIAXJN.1-adapted COVID-19 vaccineEfluelda
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on 2026-526720-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526720-49-00.